Abstract
AbstractPublic health threat coming from a rapidly developing COVID-19 pandemic calls for developing safe and effective vaccines with innovative designs. This paper presents preclinical trial results of “Betuvax-CoV-2”, a vaccine developed as a subunit vaccine containing a recombinant RBD-Fc fusion protein and betulin-based spherical virus-like nanoparticles as an adjuvant (“Betuspheres”). The aim of the study was to demonstrate vaccine safety in mice, rats, and Chinchilla rabbits through acute, subchronic, and reproductive toxicity studies. Along with safety, the vaccine demonstrated protective efficacy through SARS-CoV-2-neutralizing antibody production in mice, rats, hamsters, rabbits, and primates (rhesus macaque), and lung damage and infection protection in hamsters and rhesus macaque model. Eventually, “Betuvax-CoV-2” was proved to confer superior efficacy and protection against the SARS-CoV-2 in preclinical studies. Based on the above results, the vaccine was enabled to enter clinical trials that are currently underway.
Publisher
Cold Spring Harbor Laboratory
Reference8 articles.
1. Prevention and Control Strategies for SARS-CoV-2 Infection
2. COVID-19 vaccine tracker and landscape. World Health Organization Available at: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
3. Vaccines Candidates in Clinical Trials. COVID Available at: https://covid19.trackvaccines.org/vaccines.
4. Ritchie, H. et al. Coronavirus (COVID-19) Vaccinations. Our World in Data (2020). Available at: https://ourworldindata.org/covid-vaccinations.
5. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献